Core Viewpoint - The report highlights the performance forecasts of various A-share listed companies, indicating significant growth in sectors driven by AI computing power, resource prices, and financial market activity, while also noting challenges faced by traditional industries [4][26][30]. Group 1: Companies with Notable Performance Growth - State Grid Yingda (600517.SH) expects a net profit of 2.3 billion to 2.75 billion yuan, a year-on-year increase of 46.10% to 74.69%, driven by stable growth in its main business and significant investment returns from its financial sector [6]. - Zhongjin Gold (600489.SH) anticipates a net profit of 4.8 billion to 5.4 billion yuan, reflecting a growth of 41.76% to 59.48%, benefiting from higher gold sales prices and improved profitability in its mining operations [6]. - Shenzhen South Circuit (002916.SZ) projects a net profit of 3.154 billion to 3.342 billion yuan, with a growth of 68% to 78%, capitalizing on AI computing upgrades and increased demand in the storage market [6]. - Dongfang Securities (600958.SH) forecasts a net profit of 5.62 billion yuan, a 67.8% increase, supported by a vibrant capital market and strong performance in its wealth management and institutional business [6]. - Chengdu Xian Dao (688222.SH) expects a net profit of 104 million to 127 million yuan, a growth of 102.50% to 147.29%, driven by stable revenue growth and improved gross margins [6]. Group 2: Companies Facing Challenges - Jinjia Co. (002191.SZ) anticipates a loss of 251.95 million to 503.90 million yuan, transitioning from profit to loss due to client structure adjustments and expected impairment provisions [20]. - Mulin Sen (002745.SZ) projects a loss of 1.5 billion to 1.1 billion yuan, also moving from profit to loss due to weak demand in the European market and increased operational costs [21]. - Tianwei Vision (002238.SZ) expects a loss of 160 million to 220 million yuan, influenced by declining rental prices in the data center market and reduced revenue from traditional cable services [23]. Group 3: Industry Trends - The technology growth narrative is clear, with companies like Shenzhen South Circuit and Huadian Co. benefiting from AI computing upgrades and high-end manufacturing demands [26]. - Resource price sensitivity is evident, with companies like Zhongjin Gold and Xiamen Tungsten experiencing performance recovery due to rising prices of strategic resources [26]. - The financial sector shows resilience and transformation, with firms like Dongfang Securities and Guotai Junan benefiting from increased market activity and strategic shifts [27]. - The recovery in consumer and service industries is highlighted by Wanda Film's return to profitability, showcasing the importance of content and experiential consumption [28]. - The pharmaceutical sector is experiencing significant differentiation, with companies like Chengdu Xian Dao achieving high growth through innovation, while others face competitive pressures [29].

Core Viewpoint - Jiuan Medical's 2025 performance forecast indicates a net profit of 2.02 to 2.35 billion yuan, representing a year-on-year growth of 21.05% to 40.83% [2][3]. Group 1: Performance Overview - The company expects to maintain a high profit level in 2025, with net profit projected to exceed 2 billion yuan, significantly above pre-pandemic levels [6]. - This voluntary performance forecast, although unaudited, signals Jiuan Medical's strong profitability for 2025 [6]. Group 2: Revenue and Profit Discrepancy - Despite the profit growth, Jiuan Medical's revenue is under pressure, with a notable decline in revenue from government orders related to the pandemic and a significant drop in sales of testing kits [5][6]. - The company's operating revenue for the current period is reported at approximately 765 million yuan, down 43.35% from the previous year [7]. Group 3: Profit Sources - The increase in net profit is primarily attributed to the performance of the asset management business and stable demand for testing kits and home healthcare electronic products [11]. - Investment income and fair value changes are becoming increasingly significant in the profit structure, indicating a shift from reliance on medical product sales to asset management and investment returns [13]. Group 4: Structural Implications - Jiuan Medical's current business model is evolving into a hybrid structure that combines healthcare product sales with substantial financial asset management capabilities [14][15]. - This structural change suggests that profit stability is more dependent on asset allocation performance rather than solely on product sales or market demand [16]. Group 5: Industry Context - Jiuan Medical's performance forecast represents a non-typical profit model within the healthcare industry, highlighting the need for market participants to differentiate between traditional growth paths and those driven by asset management capabilities [19]. - The sustainability of this profit structure and its resilience to market fluctuations will require further analysis following the annual report [19].

1月27日主力资金净流入2633.27万元；游资资金净流入1098.66万元；散户资金净流出3731.93万元。 公司公告汇总2025年度业绩预告 截至2026年1月27日收盘，九安医疗(002432)报收于43.98元，上涨2.97%，换手率6.77%，成交量29.67万 手，成交额12.98亿元。 当日关注点 交易信息汇总资金流向 天津九安医疗电子股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为202,000 万元至235,000万元，较上年同期增长21.05%至40.83%；扣除非经常性损益后的净利润为207,000万元至 240,000万元，同比增长23.18%至42.81%。基本每股收益为4.6782元/股至5.4424元/股。业绩增长主要得 益于资管业务在大类资产配置方面的良好表现，以及试剂盒类产品和家用医疗健康电子产品市场需求稳 定。公司已与会计师事务所就业绩预告进行预沟通，无分歧，但预告未经审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月27日主力资金净流入2633 ...

【九安医疗】2025业绩预告：主业稳健，利润大幅增长主要系资产管理贡献 业绩概况： 2025全年：归母净利润20.2–23.5亿元（同比+21.05%~+40.83%）；扣非净利润20.7–24亿元（同比 +23.18%~+42.81%）。 2025Q4：归母净利润4.31–7.61亿元（同比+43.60%~+153.57%）；扣非净利润4.92–8.22亿元（同比+62.07%~+ 业绩概况： 2025全年：归母净利润20.2–23.5亿元（同比+21.05%~+40.83%）；扣非净利润20.7–24亿元（同比 +23.18%~+42.81%）。 2025Q4：归母净利润4.31–7.61亿元（同比+43.60%~+153.57%）；扣非净利润4.92–8.22亿元（同比 +62.07%~+170.77%）。 简评： 1）净利润同比增长主要系资管业务大类资产配置表现良好。 2）试剂盒类产品作为常规家用上呼吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 【九安医疗】2025业绩预告：主业稳健，利润大幅增长主要系资产管理贡献 ...

截至2026年1月26日收盘，九安医疗(002432)报收于42.71元，上涨0.78%，换手率3.1%，成交量13.61万 手，成交额5.77亿元。 当日关注点 交易信息汇总 资金流向 业绩披露要点 业绩预告 九安医疗发布业绩预告，预计2025年全年扣非后净利润盈利20.7亿元至24亿元。九安医疗发布业绩预 告，预计2025年全年每股收益盈利4.6782元至5.4424元。九安医疗发布业绩预告，预计2025年全年归属 净利润盈利20.2亿元至23.5亿元。 公司公告汇总 2025年度业绩预告 天津九安医疗电子股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为202,000 万元至235,000万元，较上年同期增长21.05%至40.83%；扣除非经常性损益后的净利润为207,000万元至 240,000万元，同比增长23.18%至42.81%。基本每股收益为4.6782元/股至5.4424元/股。业绩增长主要得 益于资管业务在大类资产配置方面的良好表现，以及试剂盒类产品和家用医疗健康电子产品市场需求稳 定。公司已与会计师事务所就业绩预告进行预沟通，无分歧，但预告未经审计。 以上内容为证券 ...

本报告期内，公司净利润较去年同期实现增长，主要源于资管业务在大类资产配置方面表现良好。公司 始终致力于实现资产保值增值，并持续提升风险抵御能力。此外，公司试剂盒类产品作为常规家用上呼 吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 格隆汇1月26日丨九安医疗(002432.SZ)公布，预计2025年归属于上市公司股东的净利润202,000万元～ 235,000万元，比上年同期增长21.05%～40.83%，扣除非经常性损益后的净利润207,000万元～240,000万 元，比上年同期增长23.18%～42.81%。 ...

九安医疗表示，报告期内，公司净利润较上年同期实现增长，主要源于资管业务在大类资产配置方面表 现良好。公司始终致力于实现资产保值增值，并持续提升风险抵御能力。此外，公司试剂盒类产品作为 常规家用上呼吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 北京商报讯（记者 丁宁）1月26日晚间，九安医疗（002432）发布2025年度业绩预告显示，公司2025年 预计实现归属净利润20.2亿元至23.5亿元，同比增长21.05%至40.83%。 ...

九安医疗(002432.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润20.2亿元至23.5亿 元，同比增长21.05%至40.83%;扣除非经常性损益后的净利润20.7亿元至24亿元，同比增长23.18%至 42.81%。 报告期内，公司净利润较去年同期实现增长，主要源于资管业务在大类资产配置方面表现良好。公司始 终致力于实现资产保值增值，并持续提升风险抵御能力。公司试剂盒类产品作为常规家用上呼吸道病毒 筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 ...

九安医疗（002432）(002432.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润20.2亿 元至23.5亿元，同比增长21.05%至40.83%;扣除非经常性损益后的净利润20.7亿元至24亿元，同比增长 23.18%至42.81%。 报告期内，公司净利润较去年同期实现增长，主要源于资管业务在大类资产配置方面表现良好。公司始 终致力于实现资产保值增值，并持续提升风险抵御能力。公司试剂盒类产品作为常规家用上呼吸道病毒 筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 ...

人民财讯1月26日电，九安医疗（002432）1月26日发布2025年度业绩预告，预计2025年归母净利20.2亿 元—23.5亿元，同比增长21.05%—40.83%。报告期内，资管业务在大类资产配置方面表现良好。此外， 公司试剂盒类产品作为常规家用上呼吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳 定。 ...